Fisher Asset Management LLC Has $60.86 Million Stock Holdings in Haemonetics Co. (NYSE:HAE)

Fisher Asset Management LLC decreased its holdings in Haemonetics Co. (NYSE:HAE) by 17.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 711,667 shares of the medical instruments supplier’s stock after selling 150,953 shares during the quarter. Fisher Asset Management LLC owned 1.40% of Haemonetics worth $60,855,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Parkside Financial Bank & Trust raised its stake in Haemonetics by 17.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock worth $90,000 after purchasing an additional 156 shares in the last quarter. Riverwater Partners LLC raised its stake in Haemonetics by 1.5% in the 4th quarter. Riverwater Partners LLC now owns 15,784 shares of the medical instruments supplier’s stock worth $1,350,000 after purchasing an additional 231 shares in the last quarter. Contravisory Investment Management Inc. raised its stake in Haemonetics by 7.4% in the 4th quarter. Contravisory Investment Management Inc. now owns 3,507 shares of the medical instruments supplier’s stock worth $300,000 after purchasing an additional 242 shares in the last quarter. LVZ Inc. raised its stake in Haemonetics by 9.4% in the 4th quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock worth $257,000 after purchasing an additional 259 shares in the last quarter. Finally, Keene & Associates Inc. raised its stake in Haemonetics by 3.1% in the 4th quarter. Keene & Associates Inc. now owns 8,780 shares of the medical instruments supplier’s stock worth $751,000 after purchasing an additional 268 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HAE. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. JMP Securities raised their target price on shares of Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a report on Friday, May 10th. TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a report on Wednesday, June 12th. Finally, Barrington Research raised their target price on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.50.

Insider Activity at Haemonetics

In related news, EVP Anila Lingamneni sold 2,305 shares of Haemonetics stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $95.00, for a total transaction of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $95.00, for a total transaction of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Josep Llorens sold 822 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $94.82, for a total transaction of $77,942.04. Following the sale, the executive vice president now directly owns 16,350 shares in the company, valued at $1,550,307. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,380 shares of company stock valued at $2,445,816. 1.80% of the stock is owned by insiders.

Haemonetics Trading Down 1.6 %

Shares of Haemonetics stock opened at $84.66 on Monday. The firm has a market capitalization of $4.31 billion, a PE ratio of 36.97, a price-to-earnings-growth ratio of 1.54 and a beta of 0.37. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. The firm’s 50 day moving average is $88.98 and its 200 day moving average is $83.61. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to analyst estimates of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The firm’s revenue was up 12.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.77 EPS. Equities research analysts forecast that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.